Focal epilepsy treatment progresses following positive Phase IIb results

Posted:
26
October 2021

Richmond Pharmacology’s research partner, Xenon Pharmaceuticals reported positive top line results from its Phase IIb X-TOLE clinical trial of XEN1101 – a differentiated Kv7 potassium channel modulator.

Xenon Pharmaceuticals reported positive topline results from its Phase IIb “X-TOLE” clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 – a differentiated Kv7 potassium channel modulator – administered as adjunctive treatment in adult patients with focal epilepsy.

The trial met its primary and secondary efficacy endpoints with XEN1101 demonstrating a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when compared to placebo. 

XEN1101 is being developed by Xenon for the treatment of epilepsy, major depressive disorder, and potentially other neurological disorders. Richmond Pharmacology was a key research partner during Phase I development, including first in human (FIH) studies, food effect and formulation comparisons. In particular, we conducted studies in collaboration with investigators at King’s College using transcranial magnetic stimulation (TMS) technics to evaluate the corticospinal and cortical activity profile of XEN1101 compared to placebo in healthy male volunteers. We have continued to follow XEN1101’s progression through its subsequent clinical development.

Dr. Christopher Kenney, Xenon’s Chief Medical Officer commented, “On behalf of the entire Xenon team, I wish to extend our thanks to the patients, investigators, and site coordinators who participated in the X-TOLE study. We have generated strong evidence that supports the efficacy, safety and tolerability of XEN1101 and depicts a highly favorable product profile for XEN1101.”

Dr. Jorg Taubel, Richmond Pharmacology CEO, stated, “We are delighted to see the progress of XEN1101 having conducted supporting research studies during the Phase I stage. The strength of these topline data suggest XEN1101 could play an important role in treating patients with focal epilepsy.

To learn more about the X-TOLE results, read the full news release here.

Latest news

Upcoming Event

The Future of Healthcare.

13:00 – 17:00, 8th December 2021
Join Richmond Pharmacology, The Royal Free Hospital and Richmond Research Institute as we share breakthroughs in cardiac health from gene editing to RNA interference therapies.
View event

The future of clinical workforce training programmes, an exclusive interview with MedCity

November 30, 2021
Ulrike Lorch discusses the future of clinical workforce training programmes in an exclusive interview with MedCity
Read more

Richmond Pharmacology’s Dr Emma Akuffo joins fellow EUCROF task force members as a finalist at TOPRA Awards 2021

November 17, 2021
EUCROF task force members compete for a prize at the TOPRA Awards 2021
Read more

Developing talent in the fast-changing clinical research environment

November 2, 2021
In a feature article for PharmaTimes, Dr. Ulrike Lorch, Medical Director at Richmond Pharmacology, outlines how investing in the clinical research workforce is crucial to delivering high quality, cutting-edge trials and achieving faster drug development
Read more